Maxwellia Shortlisted for Four Categories at OTC Marketing Awards 2024
Maxwellia is thrilled to announce that we have been shortlisted as finalists in four categories at the highly anticipated OTC Marketing Awards 2024. These nominations highlight our commitment to making healthcare more accessible and our ability to innovate in a highly competitive industry. The categories include:
• Best OTC Audiovisual Advertising for our Ultravana® HyperGram campaign
• Most Innovative New OTC Product for Evana® Heavy Period Relief
• OTC Brand of the Year for LoviOne®
• OTC Company of the Year
These nominations reflect the broad scope of our work in advancing consumer healthcare. At Maxwellia, we aim to transform access to medicines by switching prescription-only products into over-the-counter (OTC) treatments, giving individuals greater control over their health.
Innovative Products Making a Difference
Maxwellia’s product innovations have gained significant recognition in the market. Evana® Heavy Period Relief, launched in August 2024, is a prime example. It is the only OTC medicine for heavy periods available to women aged 18-45. Evana® offers a non-hormonal treatment, giving people who menstruate access to relief from heavy bleeding without the need for a prescription.
Meanwhile, LoviOne®, our emergency contraceptive, has been shortlisted for OTC Brand of the Year. It is accessibly priced, making emergency contraception more accessible, and has been a significant commercial success since its launch in September 2023.
Pioneering Marketing Campaigns
Maxwellia’s forward-thinking approach extends to our marketing strategies. Our Ultravana® HyperGram campaign has been nominated for Best OTC Audiovisual Advertising. This bold out-of-home activation, which took place at London’s Waterloo Station, used cutting-edge 3D technology to deliver a visually captivating, holographic message that challenged period stigmas and engaged thousands of passersby. The campaign’s use of immersive media positioned Ultravana® as a dynamic new option for period pain relief.
OTC Company of the Year
Maxwellia has also been nominated for OTC Company of the Year, a recognition of our achievements as a challenger brand in healthcare. Maxwellia has rapidly grown into a leader in the consumer healthcare market, delivering innovative OTC solutions with a lean, agile team. Our success stems from a deep understanding of consumer needs, our focus on accessibility, and a relentless drive to push boundaries in healthcare.
These nominations reflect our commitment to delivering high-quality, accessible medicines that empower consumers. We are incredibly proud to be recognised for our work and look forward to the OTC Marketing Awards ceremony on 21st November 2024.
For a full list of the 2024 finalists, please visit OTC Marketing Awards Shortlist.
Evana® Heavy Period Relief 500 mg tablets. Tranexamic acid. Ultravana® Period Pain Relief 250 mg Gastro-resistant tablets. Naproxen. LoviOne® 1.5mg tablet. Levonorgestrel. Emergency contraception. Always read the label.